BioXcel Therapeutics (BTAI) Net Cash Flow (2017 - 2026)

BioXcel Therapeutics' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$11.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 1098.88% year-over-year to -$11.6 million in Q1 2026; TTM through Mar 2026 was -$13.8 million, a 67.93% increase from a year earlier, with the FY2025 full-year figure at -$1.1 million, up 96.9% from the prior year.
• Net Cash Flow fell to -$11.6 million in Q1 2026 per BTAI's latest filing, from -$8.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $18.7 million in Q3 2025 and bottomed at -$38.6 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$15.9 million (2024), against an average of -$16.6 million.
• Across the five-year window, Net Cash Flow sank 3202.64% in 2023 and jumped 218.01% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$38.6 million in 2022, then surged by 35.89% to -$24.7 million in 2023, then jumped by 57.43% to -$10.5 million in 2024, then climbed by 18.7% to -$8.6 million in 2025, then tumbled by 35.2% to -$11.6 million in 2026.
• Per Business Quant, the three latest BTAI Net Cash Flow figures stand at -$11.6 million (Q1 2026), -$8.6 million (Q4 2025), and $18.7 million (Q3 2025).